Q-omics provides the consensus-scored NTF3 profile across patient tissues and cancer cell-line models. NTF3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, NTF3 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, NTF3 RNA expression shows 13,788 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, BLCA, and THYM as cancer lineages where NTF3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NTF3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NTF3 survival associations across molecular data types. NTF3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NTF3 RNA expression–survival associations across cancer types. High NTF3 expression shows unfavorable associations in STAD and UVM, but favorable associations in HNSC, THCA, UCS and LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for NTF3 RNA expression.
This table summarizes NTF3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for NTF3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NTF3 shows lower tumor expression in BLCA, KICH, KIRP, HNSC, LIHC and BRCA. The BLCA box plot shows higher NTF3 RNA expression in normal versus tumor tissue (log2 FC = −2.097, t-test p < 0.001).
This table shows molecular features associated with NTF3 in patient tissues and cancer cell lines. In patient samples, NTF3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NTF3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and SOFT_TISSUE.
